Company profile: StageZero Life Sciences
1.1 - Company Overview
Company description
- Provider of blood-based diagnostics for early disease detection, including ARISTOTLE, a single-sample test detecting molecular signatures of nine cancers (e.g., breast, ovarian, colorectal); ColonSentry, a gene expression blood test for early colorectal cancer without dietary restrictions or stool handling; and AVRT, a program that identifies early cancer risk factors and provides actionable lifestyle guidance.
Products and services
- ARISTOTLE®: Molecular-signature-based blood test that detects nine specific cancers—including breast, ovarian, and colorectal—from a single blood sample, enabling multi-cancer identification in one test
- AVRT™: Early-stage risk-assessment program that identifies early risk factors for cancer and delivers actionable information to help people adopt lifestyle modifications to reduce their risk
- ColonSentry®: Gene expression-based blood test that identifies colorectal cancer early without the need for dietary restrictions or stool handling, enabling detection through a blood sample
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to StageZero Life Sciences
Estrella Biopharma
HQ: United States
Website
- Description: Provider of proprietary CD19-Redirected ARTEMIS T-cell therapies for cancer, designed to treat CD19-positive blood cancers with reduced risk of CRS and neurotoxicity. Offerings include a Mark-and-Kill approach using an oncolytic virus to label solid tumors for targeting by ARTEMIS T Cells, EB104 (CD19/CD22) for blood cancers, and EB103 combined with an oncolytic virus for solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Estrella Biopharma company profile →
Kudos Pharmaceuticals
HQ: United Kingdom
Website
- Description: Provider of drug discovery and development based on the science of DNA damage sensing, signaling, and repair to address medical needs in cancer treatment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kudos Pharmaceuticals company profile →
Haystack Oncology
HQ: United States
Website
- Description: Provider of tumor-informed liquid biopsy and ctDNA detection solutions to diagnose minimum residual disease and inform therapy decisions, including Haystack MRD to detect residual/recurrent/resistant disease; Haystack Duo Chemistry for sensitive detection of low-abundance mutant DNA; and clinical trial collaborations to evaluate therapeutic response.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Haystack Oncology company profile →
Vaxess
HQ: United States
Website
- Description: Provider of needle-free vaccine and therapeutic delivery solutions, offering the MIMIX applicator with patch for skin-based administration and silk fibroin biomaterials that create stable, biocompatible delivery systems, with a focus on improving access to vaccines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vaxess company profile →
Verastem
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies targeting RAS/MAPK pathway–driven cancers, developing avutometinib, a RAF/MEK clamp designed to block RAF and MEK signaling in the RAS pathway, and defactinib, a FAK inhibitor used with avutometinib to block compensatory FAK activation and enhance tumor growth blockade.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Verastem company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for StageZero Life Sciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to StageZero Life Sciences
2.2 - Growth funds investing in similar companies to StageZero Life Sciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for StageZero Life Sciences
4.2 - Public trading comparable groups for StageZero Life Sciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →